Skip to content
    THC
    Earnings call· Jun 2026(Q2 FY26)

    TENET HEALTHCARE CORP THC

    Jul 24, 2026 Source

    Executive summary

    Tenet Q2 FY26 — Strong Performance Driven by Acuity Focus and Expense Management

    Tenet Healthcare delivered a strong Q2 FY26, exceeding goals through a strategic focus on higher acuity services and effective technology-enabled expense management. The company raised its full-year guidance, driven by fundamental business strength, despite significant headwinds from declining exchange enrollment and increasing uninsured volumes. Management remains confident in its ability to execute its strategy and deploy capital effectively.

    Highlights

    5
    • Consolidated adjusted EBITDA grew 16.3% over prior year to $1.304 billion.

    • Adjusted diluted earnings per share increased 52% to $6.12.

    • USPI adjusted EBITDA grew 8.8% to $542 million, exceeding aggressive targets.

    • Hospital segment adjusted EBITDA grew 22% to $762 million, well above expectations.

    • Full-year 2026 adjusted EBITDA guidance raised by $295 million at the midpoint to $4.83 billion-$5.03 billion.

    Concerns

    4
    • Exchange revenues declined 17% compared to Q2 FY25, representing a $65 million headwind.

    • Exchange volume admissions were down 13.5% year-over-year.

    • A proportionately equal increase in uninsured volumes was observed in Q2, expected to continue in the second half.

    • The elective surgery book in hospitals was under pressure in states experiencing high exchange enrollment declines.

    Guidance & targets

    9
    CategoryTargetConfidence
    Full-year 2026 Net Operating Revenues
    $21.9 billion to $22.5 billion
    high materiality
    High
    Full-year 2026 Adjusted EBITDA
    $4.83 billion to $5.03 billion
    high materiality
    High
    USPI Full-year 2026 Adjusted EBITDA
    $2.16 billion to $2.22 billion
    medium materiality
    High
    Hospital Full-year 2026 Adjusted EBITDA
    $2.67 billion to $2.81 billion
    medium materiality
    High
    Full-year 2026 Adjusted Free Cash Flow after NCI
    $1.825 billion to $2.055 billion
    high materiality
    High
    Full-year 2026 M&A Spend
    Exceed $300 million
    medium materiality
    High
    Q3 FY26 Consolidated Adjusted EBITDA
    23% to 24% of full year midpoint
    low materiality
    High
    Q3 FY26 USPI Adjusted EBITDA
    24% to 25% of full year midpoint
    low materiality
    High
    Supplemental Medicaid Programs Contribution
    $140 million
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    USPI
    Adjusted EBITDA grew 8.8% over Q2 FY25 to $542 million, with a 39% adjusted EBITDA margin. Same-facility system-wide revenues increased 5%, driven by a 6.3% rise in net revenue per case, partially offset by a 1.2% decrease in same-facility case volumes, reflecting a high acuity focus. Total joint replacements in ASCs saw 10% same-store volume growth.
    Same-facility system-wide revenues: 5% increaseNet revenue per case: 6.3% upSame-facility case volumes: 1.2% downSame-store volume total joint replacements in ASCs: 10% growth over prior year
    8.8%39% adjusted EBITDA margin
    Hospital Segment
    Adjusted EBITDA grew 22% to $762 million, achieving an 18% adjusted EBITDA margin. Same-hospital inpatient adjusted admissions rose 2.6%. Revenue per adjusted admissions increased 3.3% YoY, reflecting acuity growth and supplemental Medicaid revenues, partially offset by a 17% decline in exchange revenues (5.5% of consolidated net operating revenues). Exchange volume admissions were down 13.5%, leading to a proportionate increase in uninsured volumes.
    Same-hospital inpatient adjusted admissions: 2.6% riseRevenue per adjusted admissions: 3.3% increase YoYExchange revenues: 17% decline from Q2 FY25Exchange revenues as % of consolidated net operating revenues: 5.5%Exchange volume admissions: 13.5% downUninsured volumes: proportionately equal increase
    22%18% adjusted EBITDA margin

    Operational metrics

    20
    Net Operating Revenues
    $5.6 billion
    Q2 FY26

    Consolidated net operating revenues.

    Consolidated Adjusted EBITDA
    $1.304 billion16.3% growth over prior year
    Q2 FY26

    Consolidated adjusted EBITDA and margin.

    Adjusted Diluted Earnings Per Share
    $6.1252% increase compared to prior year
    Q2 FY26

    Adjusted diluted EPS.

    Year-to-Date Outperformance
    $97 million
    YTD FY26

    Fundamental outperformance across both segments.

    Cash on Hand
    $2.1 billion
    As of June 30, 2026

    Cash balance with no borrowings outstanding under line of credit.

    Share Repurchases
    5.7 million shares
    Q2 FY26

    Shares repurchased in the second quarter.

    Share Repurchases Year-to-Date
    7 million shares
    YTD FY26

    Shares repurchased year-to-date.

    Supplemental Medicaid Revenues (Favorable Out-of-Period)
    $70 million
    Q2 FY25

    Favorable out-of-period supplemental Medicaid revenues related to prior years in the second quarter of 2025.

    Exchange Revenue Headwind
    $65 million
    Q2 FY26

    Revenue headwind from declining exchange enrollment.

    Revenue Per Adjusted Admission Headwind from Exchange
    ~2%
    Q2 FY26

    Impact of exchange revenue movement on revenue per adjusted admission.

    Normalized Performance Baseline
    $2.39 billion
    FY25

    Baseline for normalized performance in 2025, used for comparison with growth and cost efficiencies.

    Growth and Cost Efficiencies
    $388 million
    FY26

    Contribution from growth and cost efficiencies, compared to FY25 normalized performance.

    Managed Care Category Mix Proportion
    down 2.7%
    Q2 FY26

    Downward trend in managed care category as a proportion of revenues, driven by exchange declines.

    Commercial Payer Classes (ex-exchange) Volume and Patient Revenue Growth
    low single digitsquarter-over-quarter
    Q2 FY26

    Growth in volume and patient revenue for commercial payers excluding exchange plans.

    Medicaid Revenue Increase Year-over-Year
    $125 millionYoY
    Q2 FY26

    Increase in Medicaid revenue compared to Q2 FY25.

    Medicaid Supplemental Payments (Out-of-Period Delta)
    ~$20 million-$25 milliondelta
    Q2 FY26 vs Q2 FY25

    Mechanical delta in supplemental payments year-over-year, excluding other growth drivers.

    Operating Expense Pressures (Professional Fees Growth)
    10%
    Since last year

    Growth in professional fees, managed per expectations.

    Full Year Normalized Growth
    14%
    FY26 vs FY25

    Growth on a normalized basis for the full year.

    Projected Growth in H2
    11%
    H2 FY26 vs H2 FY25

    Projected growth in the second half of the fiscal year, overcoming expected exchange headwinds.

    Exchange to Uninsured Conversion
    80% to 100%
    Q2 FY26

    Range of conversion from exchange admissions to uninsured admissions.

    Industry KPIs

    6
    MetricValueDetails
    Utilization trends2.6% rise%
    Same facility volumes2.6% rise%
    Payer mix supplemental payments17% decline%
    Membership covered lives by line13.5% down%
    Segment revenue operating income$542 millionUSD
    Adjusted EPS EBITDA leverage guidance$1.304 billionUSD

    Deals & partnerships

    2
    Tenet Healthcare CorporationIncrease in share repurchase authorization$2 billion

    The Board of Directors has authorized a $2 billion increase in the share repurchase program.

    VariousAmbulatory surgical acquisitionsExceed $300 million

    Based on acquisitions made so far and a robust pipeline, the company expects to exceed $300 million in full year M&A spend in 2026 for ambulatory surgical centers.

    Risks & headwinds

    4
    Payer mix shifts and insurance enrollment uncertaintyOngoing, expected to continue into H2 FY26

    Exchange revenues declined 17% compared to Q2 FY25; exchange volume admissions down 13.5% YoY; $65 million revenue headwind in Q2 FY26.

    Mitigation: Flexing cost base, building appropriate baseline, focus on continued margin strength, growth and expense initiatives.

    Increase in uninsured volumesOngoing, expected to continue in H2 FY26

    Proportionately equal increase to exchange declines.

    Mitigation: Flexing cost base, building appropriate baseline, focus on continued margin strength, growth and expense initiatives.

    Elective surgery pressure in hospitalsQ2 FY26, expected to continue in H2 FY26

    Under more pressure on the inpatient side in states with high exchange enrollment declines.

    Mitigation: Investments in hospital-based outpatient surgical programs to offset impact.

    HOPS proposal and 340B reallocationFuture, still studying

    Could be material.

    Mitigation: Still studying the proposed rule and its various moving pieces.

    What to watch in Q3 FY26

    5

    Exchange enrollment trends and uninsured conversion

    Q3 FY26, Q4 FY26
    CurrentExchange revenues down 17%, volume admissions down 13.5% YoY, 80-100% conversion to uninsured in Q2 FY26.
    TargetContinuation of Q2 trends into Q3 and Q4.

    Why it matters

    The impact of declining exchange enrollment and increasing uninsured volumes significantly affects revenue and payer mix, requiring continued cost management and growth initiatives.

    We expected after the grace periods for exchange erosion to increase, obviously, from Q1 to Q2, and then we expect the overall market trends that we saw in Q2 to roughly continue into Q3 and Q4 rest of the year, which is why we didn't change our guidance.

    Q&A highlights

    6

    Can you provide examples of the cost structure work driving margin expansion despite industry headwinds?

    Management outlined three categories: traditional productivity (contract renegotiations, supply standardization), clinical operations cost improvement (length of stay, OR/cath lab utilization), and technology/AI-driven automation, all planned in 2025 for 2026 execution.

    There's 3 or 4 things that are probably important to consider here. One is just traditional search for efficiencies... The second category is what I would describe as more clinical operations, cost improvement... And then the third area is more what I would describe as the technology-driven, both automation, AI type work.

    asked by Craig Hettenbach · answered by Saumya Sutaria

    3 min read6 chapters

    Detailed Narrative

    01

    Cost Structure Management and Efficiency Initiatives

    Management detailed a three-pronged approach to cost management, which was planned in mid-2025 and executed from January 2026. This includes traditional productivity strategies like contract renegotiations and supply standardization. The second category focuses on clinical operations cost improvement, such as length of stay management, service level management in emergency departments, and better utilization of operating room and cath lab assets. The third area involves technology-driven automation and AI initiatives, deployed both domestically and in the global business center, to improve productivity and automate tasks, contributing to core cost structure improvements.

    02

    USPI High Acuity Strategy and Service Line Expansion

    USPI continues to expand its high acuity strategy by pushing the envelope of clinical appropriateness in ambulatory surgery settings. This includes significant growth in orthopedics, particularly total joint replacements, which saw 10% same-store volume growth year-over-year. Other expanding areas include urology, general surgical robotics, and bariatrics, with a steady progression into the cardiovascular space. Additionally, USPI is increasing acuity in core legacy service lines like GI and ophthalmology by moving newer, more complex procedures from the hospital setting to ASCs.

    03

    Impact of Exchange Enrollment Declines

    The decline in exchange enrollment presented a significant headwind, with exchange revenues down 17% and volume admissions down 13.5% year-over-year in Q2 FY26, resulting in a $65 million revenue impact. This decline was most pronounced in states such as Florida, Arizona, Michigan, South Carolina, and Texas. Management noted a roughly one-to-one conversion of exchange patients to uninsured volumes, a trend expected to continue in the second half of the year, leading to pressure on the hospital elective surgery book in affected states.

    04

    Medicaid Revenue Growth and Investment

    Medicaid revenue growth is driven by Tenet's commitment to markets with heavy Medicaid populations and investments in high acuity services, such as trauma centers and neonatal intensive care units. Management emphasized that state-directed payment program monies are considered earned, as they support the capital investments and service provision required for sick Medicaid patients. Tenet continues to invest in and grow these services for all payers in its hospitals, contributing to overall revenue growth.

    05

    Capital Deployment Priorities and Shareholder Value

    Tenet prioritizes capital deployment to create shareholder value, focusing on three key areas. First, capital investments are directed towards growing USPI through M&A, with an expectation to exceed $300 million in M&A spend in 2026. Second, the company invests in key hospital growth opportunities to fuel organic growth, particularly in higher acuity service offerings. Third, Tenet remains active in share repurchases, having authorized a $2 billion increase in its program, reflecting confidence in its strategy and valuation.

    06

    Volume Trends and Market Optimism

    Despite some industry reports of volume weakness, Tenet is experiencing strong hospital volumes and same-store revenue growth, which it attributes to demographic trends, the burden of chronic disease, and the returns on its capital investments in strategic markets. Management expressed optimism, stating they are not observing a consumer pullback or systematic deferral of care in their business. They believe that focusing on access and improving service levels will continue to meet existing demand.

    AI-generated summary of the company’s earnings call. Not investment advice.